$4.86
0.61% today
Nasdaq, Apr 04, 09:15 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Target price 2025 - Analyst rating & recommendation

bluebird bio, Inc. Classifications & Recommendation:

Buy
20%
Hold
80%

bluebird bio, Inc. Price Target

Target Price $6.50
Price $4.89
Potential
Number of Estimates 4
4 Analysts have issued a price target bluebird bio, Inc. 2026 . The average bluebird bio, Inc. target price is $6.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 1 Analysts recommend bluebird bio, Inc. to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the bluebird bio, Inc. stock has an average upside potential 2026 of . Most analysts recommend the bluebird bio, Inc. stock at Hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 83.81 271.62
184.10% 224.09%
EBITDA Margin -246.34% -35.24%
76.46% 85.69%
Net Margin -288.38% -28.24%
77.34% 90.21%

6 Analysts have issued a sales forecast bluebird bio, Inc. 2025 . The average bluebird bio, Inc. sales estimate is

$272m
Unlock
. This is
224.09% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$384m 357.94%
Unlock
, the lowest is
$150m 79.03%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $83.8m 184.10%
2025
$272m 224.09%
Unlock
2026
$378m 39.30%
Unlock
2027
$277m 26.79%
Unlock
2028
$333m 20.22%
Unlock
2029
$415m 24.62%
Unlock

3 Analysts have issued an bluebird bio, Inc. EBITDA forecast 2025. The average bluebird bio, Inc. EBITDA estimate is

$-95.7m
Unlock
. This is
53.64% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$38.7m 118.74%
Unlock
, the lowest is
$-171m 17.25%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-206m 33.11%
2025
$-95.7m 53.64%
Unlock
2026
$151m 257.69%
Unlock

EBITDA Margin

2024 -246.34% 76.46%
2025
-35.24% 85.69%
Unlock
2026
39.89% 213.20%
Unlock

7 bluebird bio, Inc. Analysts have issued a net profit forecast 2025. The average bluebird bio, Inc. net profit estimate is

$-76.7m
Unlock
. This is
68.29% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$24.8m 110.26%
Unlock
, the lowest is
$-173m 28.48%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-242m 35.63%
2025
$-76.7m 68.26%
Unlock
2026
$12.1m 115.79%
Unlock
2027
$-19.2m 258.30%
Unlock
2028
$-15.2m 20.81%
Unlock
2029
$-4.5m 70.49%
Unlock

Net Margin

2024 -288.38% 77.34%
2025
-28.24% 90.21%
Unlock
2026
3.20% 111.33%
Unlock
2027
-6.92% 316.25%
Unlock
2028
-4.56% 34.10%
Unlock
2029
-1.08% 76.32%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -24.84 -7.88
35.63% 68.28%
P/E negative
EV/Sales 1.25

7 Analysts have issued a bluebird bio, Inc. forecast for earnings per share. The average bluebird bio, Inc. EPS is

$-7.88
Unlock
. This is
68.30% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.55 110.26%
Unlock
, the lowest is
$-17.78 28.48%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-24.84 35.63%
2025
$-7.88 68.28%
Unlock
2026
$1.24 115.74%
Unlock
2027
$-1.97 258.87%
Unlock
2028
$-1.56 20.81%
Unlock
2029
$-0.46 70.51%
Unlock

P/E ratio

Current -0.20 88.37%
2025
-0.62 210.00%
Unlock
2026
3.93 733.87%
Unlock
2027
-2.48 163.10%
Unlock
2028
-3.13 26.21%
Unlock
2029
-10.63 239.62%
Unlock

Based on analysts' sales estimates for 2025, the bluebird bio, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.06 75.98%
2025
1.25 69.13%
Unlock
2026
0.90 28.22%
Unlock
2027
1.23 36.61%
Unlock
2028
1.02 16.82%
Unlock
2029
0.82 19.76%
Unlock

P/S ratio

Current 0.57 94.97%
2025
0.18 69.15%
Unlock
2026
0.13 28.21%
Unlock
2027
0.17 36.60%
Unlock
2028
0.14 16.78%
Unlock
2029
0.12 19.82%
Unlock

Current bluebird bio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Barclays
Locked
Locked
Locked Mar 31 2025
JP Morgan
Locked
Locked
Locked Feb 24 2025
Wells Fargo
Locked
Locked
Locked Feb 24 2025
Barclays
Locked
Locked
Locked Dec 31 2024
B of A Securities
Locked
Locked
Locked Nov 15 2024
Barclays
Locked
Locked
Locked Nov 15 2024
RBC Capital
Locked
Locked
Locked Nov 15 2024
Analyst Rating Date
Locked
Barclays:
Locked
Locked
Mar 31 2025
Locked
JP Morgan:
Locked
Locked
Feb 24 2025
Locked
Wells Fargo:
Locked
Locked
Feb 24 2025
Locked
Barclays:
Locked
Locked
Dec 31 2024
Locked
B of A Securities:
Locked
Locked
Nov 15 2024
Locked
Barclays:
Locked
Locked
Nov 15 2024
Locked
RBC Capital:
Locked
Locked
Nov 15 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today